Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine for cognitive deficits in adolescents with neurofibromatosis type 1
NL-OMON47363Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in neurofibromatosis type 1 (NF1) comparing Lamotrigine with Placebo (2 arms). Primary endpoint: Performance intelligence. Started Oct 2014; status: active, not recruiting.
02
Drugs
lamotrigine
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NL-OMON47363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47363.